Cargando…
Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
The 3-weekly regimen of carboplatin and paclitaxel is the backbone of first line adjuvant chemotherapy for advanced ovarian cancer. The landmark Japanese Gynaecologic Oncology Group (JGOG) 3016 study demonstrated significant improvements in progression-free survival and overall survival with dose de...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189442/ https://www.ncbi.nlm.nih.gov/pubmed/30207104 http://dx.doi.org/10.3802/jgo.2018.29.e96 |
_version_ | 1783363373662994432 |
---|---|
author | Lee, Matilda X. Tan, David SP |
author_facet | Lee, Matilda X. Tan, David SP |
author_sort | Lee, Matilda X. |
collection | PubMed |
description | The 3-weekly regimen of carboplatin and paclitaxel is the backbone of first line adjuvant chemotherapy for advanced ovarian cancer. The landmark Japanese Gynaecologic Oncology Group (JGOG) 3016 study demonstrated significant improvements in progression-free survival and overall survival with dose dense weekly administration of paclitaxel in combination with 3-weekly carboplatin. However, efforts to replicate these benefits have failed in subsequent phase III trials. Weekly paclitaxel is purported to have enhanced antitumor activity, with stronger anti-angiogenic effects, and yet is better tolerated. In this review, we explore the rationale for dose dense weekly paclitaxel, and compare the relevant trials as well as quality of life considerations. Possible reasons for the difference in outcomes between the JGOG 3016 and other studies are reviewed, with a focus on how the addition of bevacizumab, the variations between histological and molecular subtypes of epithelial ovarian cancers, and ethnic pharmacogenetic differences may potentially affect the efficacy of dose dense paclitaxel. |
format | Online Article Text |
id | pubmed-6189442 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-61894422018-11-01 Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen? Lee, Matilda X. Tan, David SP J Gynecol Oncol Review Article The 3-weekly regimen of carboplatin and paclitaxel is the backbone of first line adjuvant chemotherapy for advanced ovarian cancer. The landmark Japanese Gynaecologic Oncology Group (JGOG) 3016 study demonstrated significant improvements in progression-free survival and overall survival with dose dense weekly administration of paclitaxel in combination with 3-weekly carboplatin. However, efforts to replicate these benefits have failed in subsequent phase III trials. Weekly paclitaxel is purported to have enhanced antitumor activity, with stronger anti-angiogenic effects, and yet is better tolerated. In this review, we explore the rationale for dose dense weekly paclitaxel, and compare the relevant trials as well as quality of life considerations. Possible reasons for the difference in outcomes between the JGOG 3016 and other studies are reviewed, with a focus on how the addition of bevacizumab, the variations between histological and molecular subtypes of epithelial ovarian cancers, and ethnic pharmacogenetic differences may potentially affect the efficacy of dose dense paclitaxel. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2018-11 2018-08-18 /pmc/articles/PMC6189442/ /pubmed/30207104 http://dx.doi.org/10.3802/jgo.2018.29.e96 Text en Copyright © 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Lee, Matilda X. Tan, David SP Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen? |
title | Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen? |
title_full | Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen? |
title_fullStr | Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen? |
title_full_unstemmed | Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen? |
title_short | Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen? |
title_sort | weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189442/ https://www.ncbi.nlm.nih.gov/pubmed/30207104 http://dx.doi.org/10.3802/jgo.2018.29.e96 |
work_keys_str_mv | AT leematildax weeklyversus3weeklypaclitaxelincombinationwithcarboplatininadvancedovariancancerwhichistheoptimaladjuvantchemotherapyregimen AT tandavidsp weeklyversus3weeklypaclitaxelincombinationwithcarboplatininadvancedovariancancerwhichistheoptimaladjuvantchemotherapyregimen |